

Trijardy XR - (5mg/2.5mg/1 g,10mg/5mg/1g,12.5mg/5mg/1g,25mg/5mg/1)

| | | | |
|------------------------------|---|-----------------------------|----------------------|
| Generic Name | Empagliflozin, Linagliptan and Metformin Hydrochloride | Innovator | Boehringer Ingelheim |
| Dosage | 5mg/2.5mg/1 g,10mg/5mg/1g,12.5mg/5mg/1g,25mg/5mg/1 | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | None | Generic Launches | None |
| Indication | TRIJARDY XR is a combination of empagliflozin, linagliptin, and metformin hydrochloride (HCl) indicated as an adjunct to diet and exercise to improve glycemc control in adults with type 2 diabetes mellitus | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.